Vertex VERX 深 沪
等待开盘 08-25 09:30:00 美东时间
13.585
+0.115
+0.85%
华盛通- 最 高13.82
- 今 开13.48
- 成交量 35.77万股
- 最 低 13.47
- 昨 收 13.47
- 总市值 220.37万
- 52周最高 26.54
- 市盈率 静 305.97
- 换手率 0.22%
- 52周最低 10.21
- 委 比 4.62%
- 总股本 0.00亿
- 历史最高 60.71
- 量 比 0.49
- 振 幅 2.60%
- 历史最低 9.44
- 每 手 1
- 风险率 5.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Notable healthcare headlines for the week: Moderna, Merck, and Twist Bioscience in focus
Wall Street’s major averages closed firmly higher on Friday, with Treasury yields largely steady and Bitcoin experiencing sharp intraday swings. The Dow Jones Industrial Average advanced 0.9%, the S&P...
08-23 21:05
SpaceXAI Launches Grok 4.6 On Google Cloud Vertex AI
https://x.ai/news/grok-4-6-vertex-ai
08-22 02:51
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’
On CNBC’s “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked ServiceNow, Inc. (NYSE:NOW). As per the recent news, ServiceNow, on Thursday, announced an expanded multi-year partnership with Tech Mahindra aimed at helping enterprises move AI projects from pilot programs into ful...
08-21 20:19
MNC百亿并购逻辑变了
原标题：MNC百亿并购逻辑变了 来源：动脉网 2026年全球医药领域百亿级并购热度重回高位： 6月艾伯维109亿美元拿下Apogee、GSK斥资106亿美元收...
08-21 09:09
Vertex Advances Kidney Disease Pipeline With Completed Inaxaplin Phase 2b Trial
Vertex Pharmaceuticals Inc. ($VRTX) announced an update on their ongoing clinic...
08-21 00:30
受利好消息提振，美股生物科技股普涨
默沙东与Moderna联合开发的个体化新抗原疗法Intismeran Autogene联用Keytruda在III期黑色素瘤试验中达到主要终点，并将就上市申请与...
08-19 19:21
Crinetics nears shareholder vote on Vertex merger
An update from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. On July ...
08-14 21:21
MaxCyte (MXCT) 2026财年第二季度业绩电话会议：随着与基因泰克合作扩大重申业绩指引
MaxCyte 2026财年第二季度营收下降15%至730万美元，同时成本有所下降，公司维持了2026财年业绩指引。基因泰克（Genentech）和DTx将支撑下半年的增长。
08-14 08:31
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
Royalty Pharma has agreed to provide $100 million to Zealand Pharma in exchange for rights to a 1% royalty on future sales of rusfertide, a potential first-in-class therapy for polycythemia vera. The deal includes $50 million upfront and $50 million one year later. Zealand Pharma retains a 0.25% royalty on sales above $1.5 billion, while Royalty Pharma gets 0.75% on sales beyond that threshold. The FDA has set a PDUFA date for the NDA in Q3 2026,...
08-12 20:10
VIAVI Introduces Industry's First Channel Emulator for 6G and Wi-Fi 7/8
New Vertex 6.0 recreates real-world wireless conditions in the lab for complex cellular, Wi-Fi, military and aerospace RF technologies CHANDLER, Ariz., Aug. 12, 2026 /PRNewswire/ -- VIAVI So...
08-12 18:30
